Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs)

被引:73
作者
Elder, D. P. [2 ]
Lipczynski, A. M. [1 ]
Teasdale, A. [3 ]
机构
[1] Pfizer Global R&D, Sandwich CT13 9NJ, Kent, England
[2] GlaxoSmithKline R&D, Ware SG12 0DP, Herts, England
[3] AstraZeneca R&D, Loughborough LE11 5RH, Leics, England
关键词
Alkyl and benzyl halides; Trace analysis; Potential genotoxic impurities; Active pharmaceutical ingredients; Review;
D O I
10.1016/j.jpba.2008.06.009
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
This paper continues the review of the relevant scientific literature associated with the control and analysis of potential genotoxic impurities (PGIs) in active pharmaceutical ingredients (APIs). The initial review [D.P. Elder, A. Teasdale, A.M. Lipczynski, J. Pharm. Biomed. Anal. 46 (2008) 1-8.] focused on the specific class of sulfonate esters but in this instance reference is made to the analysis of alkyl and benzyl halides and other related reactive organohalide alkylating agents. Such reactive materials are commonly employed in pharmaceutical research and development as raw materials, reagents and intermediates in the chemical synthesis of new drug substances. Consequently a great deal of attention and effort is extended by the innovative and ethical pharmaceutical industry to ensure that appropriate and practicable control strategies are established during drug development to ensure residues of such agents, as potential impurities in new drug substances, are either eliminated or minimized to such an extent so as to not present a significant safety risk to volunteers and patients in clinical trials and beyond. The reliable trace analysis of such reactive organohalides is central to such control strategies and invariably involves a state-of-the-art combination of high-resolution separation science techniques coupled to sensitive and selective modes of detection. This article reports on the most recent developments in the regulatory environment, overall strategies for the control of alkylating agents and the latest developments in analysis culminating in a literature review of analytical approaches. The literature is sub-categorized by separation technique (gas chromatography (GC), high-performance liquid chromatography (HPLC), thin layer chromatography (TLC) and capillary zone electrophoresis (CZE)) and further tabulated by API type and impurity with brief method details and references. As part of this exercise, a selection of relevant pharmacopoeial monographs was also reviewed. The continued reliance on relatively non-specific and insensitive TLC methodologies in several monographs was noteworthy. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:497 / 507
页数:11
相关论文
共 47 条
[1]   A generic approach for the determination of residues of alkylating agents in active pharmaceutical ingredients by in situ derivatization-headspace-gas chromatography-mass spectrometry [J].
Alzaga, Roberto ;
Ryan, Robert W. ;
Taylor-Worth, Karen ;
Lipczynski, Andrew M. ;
Szucs, Roman ;
Sandra, Pat .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2007, 45 (03) :472-479
[2]  
[Anonymous], 2006, QUAL RISK MAN
[3]   A stability-indicating method for the determination of melphalan and related impurity content by gradient HPLC [J].
Brightman, K ;
Finlay, G ;
Jarvis, I ;
Knowlton, T ;
Manktelow, CT .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1999, 20 (03) :439-447
[4]  
*BRIT PHARM, 2007, FENT FENT CITR MON, P843
[5]  
*BRIT PHARM, 2007, FAM MON, P857
[6]  
CLARKE C, 2004, P INT SEP C
[7]  
*COMM MED PROD HUM, 2006, GUID LIM GEN IMP
[8]   The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development [J].
Dobo, KL ;
Greene, N ;
Cyr, MO ;
Caron, S ;
Ku, WW .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2006, 44 (03) :282-293
[9]   Control and analysis of alkyl esters of alkyl and aryl sulfonic acids in novel active pharmaceutical ingredients (APIs) [J].
Elder, D. P. ;
Teasdale, A. ;
Lipczynski, A. M. .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2008, 46 (01) :1-8
[10]  
Ellison G. K., 2006, PHARM AN SCI GROUP P